Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study

Dylan M Williams,1 Sara Hägg,1 and Nancy L Pedersen1,2

1Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden and 2Department of Psychology, University of Southern California, Los Angeles, CA

ABSTRACT
Background: Higher circulating antioxidant concentrations are associated with a lower risk of late-onset Alzheimer disease (AD) in observational studies, suggesting that diet-sourced antioxidants may be modifiable targets for reducing disease risk. However, observational evidence is prone to substantial biases that limit causal inference, including residual confounding and reverse causation.

Objectives: In order to infer whether long-term circulating antioxidant exposure plays a role in AD etiology, we tested the hypothesis that AD risk would be lower in individuals with lifelong, genetically predicted increases in concentrations of 4 circulating antioxidants that are modifiable by diet.

Methods: Two-sample Mendelian randomization analyses were conducted. First, published genetic association studies were used to identify single-nucleotide polymorphisms (SNPs) that determine variation in circulating ascorbate (vitamin C), β-carotene, retinol (vitamin A), and urate. Second, for each set of SNP data, statistics for genotype associations with AD risk were extracted from data of a genome-wide association study of late-onset AD cases and controls (n = 17,008 and 37,154, respectively). Ratio-of-coefficients and inverse-variance-weighted meta-analyses were the primary methods used to assess the 4 sets of SNP-exposure and SNP-AD associations. Additional analyses assessed the potential impact of bias from pleiotropy on estimates.

Results: The models suggested that genetically determined differences in circulating ascorbate, retinol, and urate are not associated with differences in AD risk. All estimates were close to the null, with all ORs for AD ≥1 per unit increase in antioxidant exposure (ranging from 1.00 for ascorbate to 1.05 for retinol). There was little evidence to imply that pleiotropy had biased results.

Conclusions: Our findings suggest that higher exposure to ascorbate, β-carotene, retinol, or urate does not lower the risk of AD. Replication Mendelian randomization studies could assess this further, providing larger AD case-control samples and, ideally, using additional variants to instrument each exposure. Am J Clin Nutr 2019;109:90–98.

Keywords: vitamin A, vitamin C, urate, uric acid, β-carotene, Alzheimer disease, Mendelian randomization

Introduction
Late-onset Alzheimer disease (AD), the most common form of dementia, is likely to be determined by a combination of inherited genetic risk and environmental influences (1). Identifying modifiable, environmental determinants of AD is
crucial for informing public health policies to reduce disease burden in populations.

Lifelong exposure to oxidative stress is hypothesized to hasten neurodegeneration via chronic damage to DNA, lipids, and proteins by oxidation/peroxidation (2). This process could influence AD etiology prior to the development of the pathologic hallmarks of the disease, such as the formation of β-amyloid plaques and neurofibrillary tangles (3). Assuming that the mitigation of oxidative stress would lead to neuroprotection, increases in dietary-sourced and endogenous antioxidants that scavenge free radicals have been proposed as a mechanism to prevent AD onset or to slow its progression (2, 3). Consistent with this hypothesis, case-control and prospective epidemiologic studies have found evidence for lower AD risk in individuals with exposure to higher circulating concentrations of antioxidants (vitamin C, molecules in the vitamin A and E families, and uric acid/urate) or proxy measures of higher exposure (4–10). However, being observational in design, these studies are prone to substantial biases that limit causal inference, including residual confounding and reverse causation (the disease process or its effects on health-related behaviors have affected antioxidant concentrations).

Randomized controlled trials (RCTs) could help to establish the effects of circulating antioxidant modification on cognitive decline and AD risk or progression, but trial data for each exposure are unavailable, scant, or inconclusive at present (11–14). There are several reasons why past trials aimed at AD treatment may have provided null findings, including interventions that target the disease process too late in its development for efficacy (where secondary prevention might be more promising) (15). Moreover, novel trials for the primary prevention of AD would be particularly challenging to conduct, given that the pathogenesis of the disease appears to be perhaps decades in length (16). Other study designs would therefore be valuable for clarifying the role of long-term antioxidant modification in AD etiology. The aim of this study was to examine, through the use of a Mendelian randomization (MR) design (17, 18), whether genetically predicted differences in several circulating antioxidants are associated with risk of AD onset. Given that genetically determined differences in circulating exposures between individuals are lifelong and not affected by environmental traits, we hypothesized that AD risk would be lower among individuals with genetically increased circulating antioxidants if higher circulating antioxidant exposure does help to prevent AD.

Methods

Study design

A series of MR analyses were conducted using a 2-sample design (18, 19). MR entails the use of genetic variation to infer the effects of a modifiable (nongenetic) trait on outcomes of interest (17). The 2-sample approach requires the identification of genotypes that affect an exposure from ≥1 published genetic association studies for exposures of interest (the first samples) and then assessment of genotype-outcome associations for each identified genetic variant in secondary data sets, which have homogeneous characteristics (of similar genetic ancestry) to the first samples. The framework that underlies MR studies is depicted and described in Supplemental Figure 1, and detailed further elsewhere (17, 20).

Genetic variants affecting circulating antioxidants

We considered identification of genetic variants as instrumental variables for the following 5 circulating antioxidants that are modified by dietary factors and which have been linked to AD risk in observational epidemiologic studies: 1) α-tocopherol (a major molecule of the vitamin E family), 2) ascorbic acid/ascorbate (vitamin C), 3) β-carotene, 4) retinol (vitamin A), and 5) uric acid/urate. In searching for genetic instruments for the antioxidants, we prioritized consistent, replicated findings from genomewide association studies (GWASs) for the identification of single-nucleotide polymorphisms (SNPs) that determine differences in the traits. We searched for GWASs of the circulating antioxidants of interest in the NHGRI-EBI GWAS catalog (http://www.ebi.ac.uk/gwas/) and in the wider literature via the PubMed search engine. We identified GWAS findings for circulating measures of each trait of interest, with the exception of ascorbate (21–24). However, for ascorbate, there are robust, replicated findings from a meta-analysis of SNPs at a locus with an established role in vitamin C metabolism, combining data on 15,087 participants in 5 cohort studies (25).

Next, we examined the suitability of the top SNPs from these studies as instruments for the exposures of interest. In MR, plausible instrumentation of exposures should ideally be based on 1 of the following 2 criteria: 1) it is possible to use numerous variants from various loci that affect the exposure independently, which enables additional methods to test for violations of instrumental variable assumptions, and 2) variants are located in or near single genes with established pathways linking the gene(s) specifically to effects on an exposure (26). With 30 independent SNPs used to instrument urate, this analysis fulfilled the first criterion. A genetic score for higher circulating urate is associated with the risk of gout (caused by hyperuricemia)— providing positive control evidence that these variants can be used to proxy urate exposure (21). Instrumenting of ascorbate, β-carotene, and retinol each fulfilled the second criterion. The SNP identified as an instrument for ascorbate is a missense variant in an exon of Solute Carrier Family 23 Member 1 (SLC23A1), which encodes sodium-dependent vitamin C transporter 1 (SVCT1), 1 of 2 cotransporters involved in the intestinal absorption and active transport of dietary ascorbate (25). SNPs instrumenting β-carotene are in beta-carotene oxygenase 1 (BCO1/alias BCMO1), which encodes the enzyme caroteno 15,15′-monooxygenase, responsible for catalyzing the cleavage of carotenoids into retinal in the small intestine (22). Rare loss-of-function mutations in this gene can produce hypercarotenemia, because excess carotenoids are not removed from circulation (as required for hepatic storage in the form of vitamin A) (27). The SNP used to instrument retinol is located near retinol binding protein 4 (RBP4), encoding retinol-binding protein 4, the major carrier that facilitates the transport of retinol from liver stores to peripheral tissues. Deleterious mutations in RBP4 produce nominal circulating retinol (28) and may lead to vitamin A–related disorders, such as retinitis pigmentosa (29). Although GWAS has identified 3 hits for circulating α-tocopherol (22, 23), these findings provided neither numerous instruments for the exposure nor the specificity of the SNPs as determinants of α-tocopherol only [the 3 loci play clear roles in lipid metabolism (22)]. We therefore chose not to proceed with MR analyses of α-tocopherol and AD risk.

Genetic association study samples were largely from cohort studies representative of general populations (some samples
were derived from RCTs), and all used data on participants of European ancestry only. Figure 1 summarizes the variant selection, along with specific methods used for analyses of each antioxidant in relation to AD risk. A full list of SNP identifiers (rs numbers) and associated information for variants used in the analyses are shown in Supplemental Table 1.

The AD case-control sample

The sample for examining genotype-outcome associations consisted of 17,008 late-onset AD cases and 37,154 controls of European ancestry included in the stage 1 GWAS meta-analysis conducted by the International Genomics of Alzheimer’s Project (IGAP) (30). IGAP has published summary statistics of genotype-AD associations for 7,055,881 SNPs online (http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php). Cases within the consortium’s cohorts had mean ages of onset ranging from 68.5 to 82.3 y, and ~60% were women. More details on the stage 1 studies, participants, genotype data, AD diagnostic criteria, and statistical models are described in the published GWAS (30), and constituent studies are listed in Supplemental Table 2. The analyses included adjustment for principal components to control for population stratification, which could bias GWASs (and thus MR results as well) if not accounted for.

Sample overlap

We attempted to quantify the degree of overlap between participants included in the GWAS of antioxidants and the study by the AD consortium, which could bias 2-sample MR results if substantial (31). The online supporting material includes full commentary (Supplemental Methods) and details of cohort numbers (Supplemental Table 2 and Supplemental Tables 3–5). The risk of bias from sample overlap in all analyses appeared to be low.

Main models

For each SNP associated with circulating antioxidants, we extracted \( \beta \) coefficients and SEs for the SNPs’ effects on antioxidant concentrations from published genetic association studies of the traits and also the corresponding \( \beta \) coefficients and SEs for the SNP associations with AD risk from IGAP data (reported as differences in log-odds). These statistics were harmonized to ensure that they corresponded to the same forward strand allele for each SNP, all of which increase antioxidant concentrations.

MR estimates of the magnitudes to which long-term variation in antioxidants might affect AD risk (the primary outcome) were produced using the ratio of coefficients method (19). Wald estimators were calculated for each SNP by dividing the estimated \( \beta \) coefficient for its association with AD risk by the \( \beta \) coefficient for its association with antioxidant. SEs for each estimator were calculated by the delta method (32).

For urate, the estimates for all variants were combined in a fixed-effects meta-analysis using inverse-variance weighting (IVW) models (i.e., combining 30 individual SNP estimates). The overall IVW meta-analysis results provide more precision for effect estimation than individual SNP-AD associations alone. The genotypes of individual SNPs used in combinations for the 3 traits were not correlated [i.e., not in linkage disequilibrium (LD)] and so each of the several AD effect estimates were independent of one another. For \( \beta \)-carotene, we combined estimators from 4
variants at a single locus (the \textit{BMCO1} gene) that were assessed in a fine-mapping association study of \(\beta\)-carotene with genetic variation in this gene (33), expanding on the findings from a previous GWAS of \(\beta\)-carotene (22). These 4 variants were modestly correlated due to LD (all pairwise Pearson’s \(r \leq \pm 0.32\); \(R^2 < 0.2\)) but still explain more variation in circulating \(\beta\)-carotene when combined than the single strongest GWAS hit at the locus does alone (33). The use of multiple correlated variants together therefore increases the statistical power for estimating the effect of \(\beta\)-carotene variation on AD risk, but would also bias the precision of an IVW estimate without appropriate weighting for the correlated variants, because the constituent individual estimates are assumed to be independent (34). Instead, we used an extension of the IVW method for the meta-analysis of \(\beta\)-carotene estimates, which included adjustment for a matrix of correlations between the SNPs (shown in \textbf{Supplemental Table 6}) (35). The matrix was derived from SNP correlations in reference data on participants of European ancestry in the 1000 Genomes project, phase 3 (36). Models for ascorbate and retinol used single Wald estimators for the sole SNPs that instrument these antioxidants specifically, and thus meta-analysis models were not conducted for these traits.

All results were reformatted by exponentiation to be expressed as ORs and 95% CIs for AD per long-term genetically predicted higher exposure to the circulating antioxidants. These results correspond to increased exposure in original units of measure for urate (milligrams per deciliter) and ascorbate (micromoles per liter). The GWASs of \(\beta\)-carotene and retinol were conducted on logn-transformed values; for ease of interpretation, we reformatted the ratio of geometric means and SEs for SNP associations with the antioxidants as relative percentage differences (37). Ensuing Wald estimators for these 3 traits were then scaled to be expressing AD risk as ORs with CIs according to 10% relative increases in concentrations of \(\beta\)-carotene and retinol.

### Antioxidant associations with AD risk factors

As shown in Supplemental Figure 1, key model assumptions in MR can be violated by horizontal pleiotropy, where variants affect outcome risk via combinations of potential confounders and alternate pathway(s), independently of their effects on the exposures of interest (20). To test whether this could bias the main findings, we examined whether the SNPs used as instruments may also be determinants of several other major risk factors for (and potential causes of) AD. We addressed several traits for which published genome-wide summary statistics are also available in open access: years of education attained, likelihood of smoking initiation, adiposity (measured by BMI), and cardiometabolic traits (triglycerides, LDL cholesterol, fasting glucose, and insulin). The GWAS data sets used for these analyses are described in \textbf{Supplemental Table 7}. All participants were of European ancestry, and sample sizes ranged from 21,544 to 322,154. For MR estimates of effects of antioxidants on these traits, we performed the same primary MR analyses as were conducted for main AD analyses, that is, using IVW methods for urate and \(\beta\)-carotene analyses and producing single Wald estimators for ascorbate and retinol.

### Further pleiotropy tests for urate analysis

In the urate analysis, where we had multiple independent SNPs to instrument the exposure, we performed a series of additional checks for evidence of bias on MR effect estimates due to horizontal pleiotropy. In brief, these involved the use of meta-analysis heterogeneity statistics, alternate MR methods (weighted median, weighted mode, and MR-Egger analyses), funnel plotting, and a sensitivity analysis (26, 38–41). Full details on these analyses are described in the Supplemental Methods. These pleiotropy-testing methods were not applicable for the ascorbate, \(\beta\)-carotene, and retinol analyses due to the small number of SNPs being used to instrument these traits.

### Additional sensitivity analyses

Where IVW models were conducted (for urate and \(\beta\)-carotene), we repeated analyses using a likelihood-based approach, which encompasses the uncertainty in SNP-antioxidant exposures more accurately than the simple weighting applied in IVW (42). The likelihood model for the \(\beta\)-carotene–AD analysis included adjustment for SNP correlations, as described for the corresponding IVW model.

### Power calculations and tests of "weak instrument" bias

To examine whether we had a sufficient sample size to undertake the MR analyses, we conducted power calculations using a published calculator (43). This estimated the power for analyses to detect minimum ORs for AD risk per SD difference in antioxidant concentrations. The calculations used the study-level average \(R^2\) statistics for variance explained in each antioxidant by the combination of SNPs determining trait variation (ranging from 0.5% to 7.0%), along with the sample size (\(n = 54,162\)) and proportion of cases (0.314) in the stage 1 IGAP sample.

To assess whether instrumental variable models could be biased by the use of "weak instruments" (where variants may not be robustly confirmed determinants of antioxidant variation), we examined any reported \(F\) statistics from genetic association analyses of the SNPs in use and corresponding antioxidants and estimated the anticipated \(F\) values from reported \(R^2\) values and sample sizes used in these studies where these were not found directly reported in the relevant publications.

### Software

Analyses were conducted in R software version 3.2.2, with the use of packages MR Base and MendelianRandomization (44, 45). Plots were produced in Stata version 15.1 (StataCorp LLC) using the package \texttt{mmrobust} (46).

### Ethics

This research involved only the reuse of existing published results and study-level summarized data and therefore did not require separate ethical approval. All genetic association studies of circulating antioxidants had obtained relevant ethical approval and informed consent from study participants (21–25, 33). Written informed consent was obtained from study participants in IGAP or, for those with substantial cognitive impairment, from...
Predicted exposure to circulating antioxidants may influence AD risk, according to results from Mendelian randomization (MR) analyses (1). A meta-analysis (Table 1) showed an association between genetically increased urate exposure and AD risk, with an odds ratio (OR) of 1.03 (95% CI: 0.96, 1.10) per long-term 10% higher exposure. This result was consistent across all MR methods, including the inverse-variance weighted (IVW) method, with no evidence of heterogeneity (I² = 0%). The MR-Egger intercept test (P = 0.33) indicated no evidence of pleiotropy bias. Additionally, sensitivity analyses using a subset of 14 SNPs as instruments for urate exposure showed consistent results, without significant residual confounding or pleiotropy (P = 0.88).

**TABLE 1** Associations of long-term, genetically increased circulating antioxidants with AD risk from MR analyses

| Trait         | Number of SNPs determining trait variation | Approximate total variance in trait explained by SNPs, % | MR estimate for AD risk, OR (95% CI) |
|---------------|------------------------------------------|-----------------------------------------------------|-------------------------------------|
| Ascorbate     | 1                                        | 0.9                                                 | 1.00 (0.99, 1.02)                   |
| β-Carotene    | 4                                        | 6.1                                                 | 1.02 (1.00, 1.03)                   |
| Retinol       | 1                                        | 0.5                                                 | 1.05 (0.94, 1.18)                   |
| Urate         | 30                                       | 7.0                                                 | 1.03 (0.96, 1.10)                   |

1. n = 17,008 cases and 37,154 controls. AD, Alzheimer disease; MR, Mendelian randomization; SNP, single-nucleotide polymorphism.
2. Variances are R² values (reformatted as percentages) reported in relevant genetic association studies (21, 24, 33, 47).
3. Results are based on the fixed-effects inverse-variance weighted method for meta-analyzing individual SNP results (urate and β-carotene) or single SNP Wald estimators (ascorbate and retinol). ORs (95% CIs) show risk of AD per long-term unit increase in exposure to circulating ascorbate (μmol/L) and urate (mg/dL) and per long-term 10% higher exposure to circulating β-carotene and retinol.

Results

In primary results (Table 1) there were no apparent differences in AD risk according to genetically predicted increases in exposure to circulating ascorbate, retinol, or urate. Higher predicted exposure to circulating β-carotene was associated with marginally elevated AD risk—although the OR was similar to results for other antioxidants, it was estimated with more precision. Figure 2 shows a scatterplot of individual urate results, along with the meta-analysis IVW estimate; the lack of trend indicates a null finding.

Figure 3 shows MR estimates for effects of antioxidant exposure on AD risk factors. Overall, there was little evidence for associations of genetically predicted differences in circulating antioxidants with lifestyle and cardiometabolic traits. The most prominent exceptions were inverse associations of β-carotene with triglycerides, and retinol with smoking initiation, and possible associations of retinol with higher BMI and urate with higher triglycerides (however, no association would survive Bonferroni correction for multiple testing).

Supplemental Table 8 shows results of MR estimates for the effect of exposure to urate on AD risk produced with 4 models that differ from IVW—namely, a maximum likelihood alternative and weighted median, weighted mode, and MR-Egger methods. The results were largely consistent with the primary IVW model. There was no suggestion of overall directional (nonneutral) bias from pleiotropy in estimates from the MR-Egger intercept test (P = 0.22) or that the MR-Egger estimate of effect would be biased toward the null by measurement error in urate instrumentation (I² = 99.4%) (48). Heterogeneity statistics indicated that there was limited inconsistency between individual SNP estimates within meta-analyses (IVW model Q test P value = 0.48), also indicative of no pleiotropic bias; a forest plot depicts this consistency (Supplemental Figure 2).

Additional steps taken to further assess whether pleiotropy had influenced the results for the effect of urate on AD risk also indicated no substantial bias in the findings. The funnel plot for urate results showed no asymmetry, with results consistently spread around the null irrespective of the size of the effect on urate (Supplemental Figure 3). In the sensitivity analyses using a subset of 14 SNPs as instruments for urate, results from all MR models were consistent with those using the 30 SNPs but with slightly less precision. For example, the OR for AD risk from the fixed-effects IVW estimate in the subset analysis was 1.03 (95% CI: 0.94, 1.12).

Illustrative power calculations suggested that the IGAP sample size and genetic instrumenting of β-carotene and urate should allow for identification of small associations with AD risk in MR models (Supplemental Table 9). In contrast, the lower variances in circulating ascorbate and retinol that are instrumented by SNPs in these analyses implies that variation in exposure to these traits would need to have moderate to large effects on AD risk for identification of genetically predicted associations to be probable in these MR models.

An evaluation of observed or estimated F statistics from genetic association analyses of variants and the antioxidants suggested no evidence of weak instrument bias in analyses. All F values were >10, the threshold under which weak instrument bias may be expected (42). A previous MR study using the variant...
rs33972313 as an instrument for circulating vitamin C exposure reported an $F$ value of 30 for the SNP-ascorbate association, estimated from a sample size of 3512, and an $R^2$ of 0.009 for variance in ascorbate explained by the SNP (47). $F$ values estimated from sample sizes and $R^2$ values of other analyses were $\sim 152$ for the combined $\beta$-carotene instruments (from $n = 2344$; $R^2 = 0.061$) (33), $\sim 47$ for the single retinol SNP ($n = 9302$; $R^2 = 0.005$) (24), and $\sim 8305$ for the combined urate instruments ($n = 110,347$; $R^2 = 0.07$) (21).

Discussion

The findings of these MR analyses suggest that increasing individuals’ long-term exposure to circulating ascorbate, $\beta$-carotene, retinol, and urate would not mitigate their risk of developing AD. All estimates of effects of antioxidant exposure on AD risk were close to null, with ORs for retinol, $\beta$-carotene, and urate $> 1$, implying that higher exposure confers slightly more risk of AD (if any difference at all), rather than neuroprotection.

These MR results contrast with findings from several sources of conventional epidemiologic evidence (summarized in Table 2 for ease of reference). In meta-analyses of AD case-control studies with circulating micronutrient measures, combined estimates suggested AD cases have lower concentrations of $\alpha$-tocopherol, ascorbate, and retinol than controls ($\beta$-carotene studies were not included) (4). Prospective studies addressing associations of these exposures with later AD incidence to date have relied on baseline dietary intake measures, rather than assay data (10, 49–54). A meta-analysis reported associations of lower intake of ascorbate, $\beta$-carotene, and vitamin E with later risk of AD onset (retinol studies were not addressed) (8). Elevated exposure to urate—regarded as a potent endogenous antioxidant, influenced by dietary intake of purines (55, 56)—has also been proposed as a candidate for AD prevention (57). National register–based studies have observed AD and dementia incidences to be lower than expected among aging individuals with a history of gout, a condition caused by hyperuricemia (6, 58). Moreover, in meta-analyses of case-control and prospective studies, lower circulating urate was also associated with higher risk of both AD (combining 24 studies) and all-cause dementia (combining 31 studies) (59, 60). However, a recent umbrella review highlighted a lack of credibility of these meta-analysis results (61).

Systematic biases in past observational studies could explain the disparities between previous findings and these MR results. Studies of dietary components as health exposures may be particularly prone to residual confounding, because dietary factors are highly correlated with one another (62) and with a multitude of other lifestyle and socioeconomic traits. Hence,
antioxidant status may closely proxy wider risk factors for AD, and particularly overall dietary patterns, which could have complex effects on disease risk that are not produced by sole micronutrient measures individually. Case-control studies often cite associations of antioxidants with AD status as evidence of the potential for antioxidant modulation to prevent AD, but these findings may have arisen from reverse causation. For instance, AD patients may have altered intake, uptake, or utilization of antioxidants; that is, lower circulating antioxidant concentrations in AD cases may reflect disease-driven physiologic differences or malnutrition (4, 63–65). In contrast, MR studies can circumvent bias from confounding and reverse causation. There could be other important violations to MR assumptions (discussed below), but if these findings are reliable, they would suggest that previous observational studies may have overstated the role of circulating concentrations of antioxidants in AD development.

The major strength of this study was the use of MR analyses, which differ substantially from prior studies and add to the evidence base for causal inference regarding these questions. The use of the 2-sample design and the very large volume of case-control data allowed analyses with sufficient power to detect even small to modest effects for β-carotene and urate (although with less power for ascorbate and retinol). Various methodologies were utilized to examine for model violations (chiefly from pleiotropy) in different ways, increasing the robustness of most results.

Two-sample MR models have several general limitations, including assumptions of linear associations, lifelong (not time-sensitive) effect estimations, and the possibilities of inference being biased by genetic phenomena such as canalization and confounding by LD between variants or sample structures, i.e., population stratification (controlled for by principal components in these AD models)—these are discussed in detail elsewhere (17, 31, 66). However, there are also specific constraints on the current evidence due to the SNPs used to instrument antioxidants.

First, the use of variants at single loci to instrument ascorbate, β-carotene, and retinol precluded several sensitivity analyses to check for bias in these 3 results due to pleiotropy (as were conducted for urate). Second, the use of single SNPs to instrument ascorbate and retinol also limited the power of these analyses, even with the very large AD case-control sample available. Larger GWASs that confirm many independent SNPs as instruments for these antioxidants would improve further MR studies by both increasing power and allowing for more nuanced testing of bias due to pleiotropy. Third, although β-carotene was instrumented more strongly than ascorbate and retinol, using multiple variants at the BCO1 locus, this gene appears to have antagonistic effects on different carotenoid concentrations; that is, alleles increasing β-carotene and other major carotenoids also lower lycopene and lutein (22). Rather than predicting β-carotene variation solely, these results should therefore be regarded as instrumenting more complex changes in carotenoid concentrations affected by this gene region simultaneously. However, any inference based on the use of these variants may still largely mimic any effects of β-carotene supplementation, were major carotenoid supplementation to similarly displace minor carotenoids from circulation (22, 67).

In conclusion, this evidence casts doubt on the role of several circulating antioxidants in AD prevention and suggests caution toward planning RCTs to test the effect of related nutritional supplements or urate-elevating therapeutics on AD risk. Future MR studies could aim to expand on these findings with larger replication samples of genetic data on AD cases and controls, ideally using a higher number of variants to instrument each exposure, if more are identified through increasingly large GWASs of circulating antioxidants (which might also permit robust analyses for vitamin E). Where genetic data become available for AD patients with disease progression measures, future MR studies could also help to evaluate whether circulating antioxidant modifications may provide disease-modifying treatments, even if not useful traits to consider for disease prevention (68).

### Table 2: Summary of meta-analyses and other large-scale observational data on associations of 4 major antioxidants and AD risk

| Antioxidant | Study type (reference) | Exposure measurement | Sample size, cases; noncases | Main findings: association estimate (95% CI) |
|-------------|------------------------|----------------------|-----------------------------|------------------------------------------|
| Ascorbate   | Meta-analysis of case-control studies (4) | Circulating concentrations | 223; 211 | Age-adjusted mean difference in cases: −14.2 μmol/L (−22.2, −6.3 μmol/L) |
| β-Carotene | Meta-analysis of prospective studies (8) | Estimated dietary intake of vitamin C | 1043; 13,468 | Relative risk for highest intake group: 0.83 (0.72, 0.94) |
| Retinol     | Meta-analysis of case-control studies (4) | Estimated dietary intake of carotenoids | 801; 9445 | Relative risk for highest intake group: 0.88 (0.73, 1.02) |
| Urate       | Meta-analysis of case-control studies (59) | Circulating concentrations | 310; 674 | Age-adjusted mean difference in cases: −0.4 μmol/L (−0.6, −0.2 μmol/L) |
|            | Meta-analysis of prospective studies (59) | Weighted mean difference: −0.77 mg/dL (−1.18, −0.36 mg/dL) | 1128; 2498 |
|            | Register-nested prospective study (6) | History of gout (indicative of high urate exposure) | 661; 6666 | Risk ratio in group with highest concentrations: 0.66 (0.52, 0.85) |
|            |                                      |                      | 2251; 295,778 | Adjusted AD HR in gout cases (high urate exposure group): 0.76 (0.66, 0.87) |

1AD, Alzheimer disease.
2Numbers reflect case-control samples, or for prospective studies, incident cases and healthy individuals at end of follow-up.
3These numbers reflect minimum incident dementia or AD cases (this is not explicitly stated in 1 of 3 studies that was meta-analyzed) from a total sample of 7327 listed in the meta-analysis.

First, the use of variants at single loci to instrument ascorbate, β-carotene, and retinol precluded several sensitivity analyses to check for bias in these 3 results due to pleiotropy (as were conducted for urate). Second, the use of single SNPs to instrument ascorbate and retinol also limited the power of these analyses, even with the very large AD case-control sample available. Larger GWASs that confirm many independent SNPs as instruments for these antioxidants would improve further MR studies by both increasing power and allowing for more nuanced testing of bias due to pleiotropy. Third, although β-carotene was instrumented more strongly than ascorbate and retinol, using multiple variants at the BCO1 locus, this gene appears to have antagonistic effects on different carotenoid concentrations; that is, alleles increasing β-carotene and other major carotenoids also lower lycopene and lutein (22). Rather than predicting β-carotene variation solely, these results should therefore be regarded as instrumenting more complex changes in carotenoid concentrations affected by this gene region simultaneously. However, any inference based on the use of these variants may still largely mimic any effects of β-carotene supplementation, were major carotenoid supplementation to similarly displace minor carotenoids from circulation (22, 67).

In conclusion, this evidence casts doubt on the role of several circulating antioxidants in AD prevention and suggests caution toward planning RCTs to test the effect of related nutritional supplements or urate-elevating therapeutics on AD risk. Future MR studies could aim to expand on these findings with larger replication samples of genetic data on AD cases and controls, ideally using a higher number of variants to instrument each exposure, if more are identified through increasingly large GWASs of circulating antioxidants (which might also permit robust analyses for vitamin E). Where genetic data become available for AD patients with disease progression measures, future MR studies could also help to evaluate whether circulating antioxidant modifications may provide disease-modifying treatments, even if not useful traits to consider for disease prevention (68).
We thank the IGAP for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report.

The authors’ responsibilities were as follows—DMW: conceived the study concept, conducted the statistical analysis, and drafted the manuscript and is the guarantor for the final content; DMW, SH, and NLP: were involved in designing the study, interpreting the data, and revising the manuscript for final submission; and all authors read and approved the final manuscript. None of the authors had any conflicts of interest to declare.

References

1. Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Trans Med 2011;3(77):77ra1.
2. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993;90(17):7915–22.
3. Nunomura A, Castellani RJ, Zhu X, Moreira PL, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65(7):631–41.
4. Lopes da Silva S, Vellas B, Elefants S, Luchinger J, Kamphuis P, Yaffe K, Sijben J, Groenendijk M, Stijnen T. Plasma nutrient status of patients with Alzheimer’s disease: systematic review and meta-analysis. Alzheimers Dement 2014;10(4):485–502.
5. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain 2009;132(Part 2):377–82.
6. Lu N, Dubreuil M, Zhang Y, Neogi T, Rai SK, Ascherio A, Hernan MA, Choi HK. Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Neurol Dis 2016;75(3):547–51.
7. Latourte A, Soumaré A, Bardin T, Perez-Ruiz F, Debette S, Ritchie P. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Neurol Dis 2017;77(3):8.
8. Li F-J, Shen L, Ji H-F. Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer’s disease: a meta-analysis. J Alzheimers Dis 2012;31(2):253–8.
9. Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, Zhao Q-F, Li J-Q, Wang J, Yu J-T. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neuro Neurosurg Psychiatry 2015;86(12):1299–306.
10. Devore EE, Grodstein F, van Rooij FA, Hofman A, Stamper MJ, Witteman JC, Breteler MM. Dietary antioxidants and long-term risk of dementia. Arch Neurol 2010;67(7):819–25.
11. Farina N, Llewellyn D, Isaac MG, Tabet N, Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Lbr 2017;4:CD002854.
12. Arlt S, Müller-Thomsen T, Beisiegel U, Kontush A. Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease. Neurochem Res 2012;37(12):2706–14.
13. Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians’ Health Study II. Arch Intern Med 2007;167(20):2184–90.
14. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, et al. A double-blind, placebo-controlled trial of selegiline, alpha-tocopherol, or both as treatment for patients with mild Alzheimer’s Disease. J Neuropathol Exp Neurol 2006;65(7):631–41.
15. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Trans Med 2011;3(111):111cm33.
16. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70(11):960–9.
17. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27(8):1133–63.
18. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 2016;103(4):965–78.
19. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 2013;178(7):1177–84.
20. Swerdlow DI, Kuchenbecker KB, Shah S, Sofat R, Holmes MV, White J, Mindell J, Kivimaki M, Brunner EJ, Whitaker JC. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol 2016;45(5):1600–16.
21. Kottgen A, Albrecht E, Teunier A, Vitar V, Krummies J, Hundertmark C, Patisis G, Ruggiero D, O’Seaghdha CM, Haller T, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013;45(2):145–54.
22. Ferrucci L, Perry JR, Matteini A, Porella M, Tanaka T, Silander K, Rice N, Melzer D, Murray A, Chlutt C, et al. Common variation in the beta-carotene 15,15′-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 2009;84(2):123–33.
23. Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, Wright ME, Yeager M, Snyder K, Weinstein SJ, Mondul A, et al. Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet 2011;20(19):3876–83.
24. Mondul AM, Yu K, Wheeler W, Zhang H, Weinstein SJ, Major JM, Cornelis MC, Mannisto S, Hazra A, Hsing AW, et al. Genome-wide association study of circulating retinol levels. Hum Mol Genet 2011;20(23):4724–31.
25. Thompson NJ, Forrest SJ, Brion M-J, Harbord RM, Cook DG, Johnson P, Macconnachie A, Morris RW, Rodriguez S, Luu JA. Genetic variation at the SLC23A1 locus is associated with circulating concentrations of L-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr 2010;92(2):375–82.
26. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology 2017;28(1):30–42.
27. Lindqvist A, Sharvill J, Sharvill DE, Andersson S. Loss-of-function mutation in carotenoid 15, 15′-monooxygenase identified in a patient with hypercarotenemia and hypovitaminosis A. J Nutr 2000;130(7):2346–50.
28. Bielsański HK, Frank J, Beck SC, Heinrich F, Illek B, Reifen R, Gollnick H, Seeliger MW, Wissing S, Zrenner E. Biochemical but not clinical vitamin A deficiency results from mutations in the gene for retinol binding protein. Am J Clin Nutr 1999;69(5):931–6.
29. Cukras C, Gaasterland T, Lee P, Gudiseva HV, Chavari VR, Pulkتاحandam R, Maranha B, Edsall L, Soares S, Reddy GB. Exome analysis identified a novel mutation in the RBP4 gene in a consanguineous pedigree with retinal dystrophy and developmental abnormalities. PloS One 2012;7(11):e50205.
30. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, De Stefano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013;45(12):1458–9.
31. Lawlor DA. Commentary: On Gao C et al. Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. Int J Epidemiol 2016;45(3):dyw127.
32. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of bias in nongenetic observational studies using “Mendelian triangulation” by Bautista et al. Ann Epidemiol 2007;17(7):511–3.
33. Hendrickson SJ, Hazra A, Chen C, Eliaissé AH, Kraft P, Rosner BA, Willett WC. β-Carotene 15,15′-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr 2012;96(6):1379–89.
34. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med 2016;35(11):1880–906.
35. Burgess S, Scott RA, Timpson NJ, Smith GD, Thompson SG, Consortium E-I. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015;30(7):543–52.
36. The Genomes Project C. A global reference for human genetic variation. Nature 2015;526(7571):68–74.
37. Cole T. Sympercents: symmetric percentage differences on the 100 loge scale simplify the presentation of log transformed data. Stat Med 2000;19(22):3109–25.
38. Greco M, Del F, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med 2015;34(21):2926–40.

39. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44(2):512–25.

40. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013;37(7):658–65.

41. Bowden J, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017;46(6):1985–98.

42. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44(2):512–25.

43. Moore KG, Scott LJ, Schizophrenia Genetics Consortium. Assessing the suitability of summary data for two-sample summary Mendelian randomization analyses using MR-Egger regression. Int J Epidemiol 2017;46(6):1734–9.

44. Spiller W, Davies NM, Palmer TM. Software application profile: mrobust - a tool for performing two-sample summary Mendelian randomization analyses. bioRxiv 2017.

45. Kobylecki CJ, Afzal S, Smith GD, Nordestgaard BG. Genetically high plasma vitamin C, intake of fruit and vegetables, and risk of ischemic heart disease and all-cause mortality: a Mendelian randomization study. Am J Clin Nutr 2015;101(6):1135–43.

46. Wang J, Deo R, Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis P, Blettner M, Witschi T, Collins R, Deloukas P. Genome-wide association study and Mendelian randomization of gout in men. Int J Epidemiol 2017;46(6):1985–98.

47. Tabet N, Mantle D, Walker Z, Orrell M. Endogenous antioxidant defenses and oxidative stress markers in erythrocytes of normal and Alzheimer patients. J Nutr Health Ageing 2001;30(3):235–41.

48. Matzke R, Schmidt I, Stahl E, Lonnqvist J, Laatikainen L, Rasanen L, Viitasalo J, Ritvanen A. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age 1995;18(3):179–88.

49. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

50. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

51. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

52. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

53. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

54. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

55. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

56. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

57. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

58. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

59. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

60. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

61. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

62. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.

63. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60(2):203–8.